GlassScriptPhysician profile
Steven C Merrill
NPI 1578582342
$4,550.14
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $967 · 2021: $984 · 2022: $972.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $730.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $518.55 | 2019-2022 | |
| Amgen INC. | $516.27 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $354.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $317.61 | 2019-2022 | |
| Amarin Pharma, INC. | $247.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.90 | 2019-2022 | |
| Lilly USA, LLC | $207.47 | 2019-2022 | |
| Allergan, INC. | $200.81 | 2019-2020 | |
| Pfizer INC. | $192.61 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $151.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $142.58 | 2019-2022 | |
| Abbvie INC. | $119.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.48 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $80.57 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $60.49 | 2019 | |
| Astellas Pharma US INC | $57.01 | 2021-2022 | |
| Almatica Pharma LLC | $49.53 | 2022 | |
| Valeritas, INC. | $37.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.72 | 2019-2020 | |
| Abbott Laboratories | $24.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.19 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.51 | 2022 | |
| Organon LLC | $15.01 | 2022 | |
| Neurocrine Biosciences, INC. | $13.46 | 2020 | |
| Sanofi Pasteur INC. | $11.78 | 2019 | |
| Shire North American Group INC | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.